Tools   Select Another Resource Report Type

http://www.yahrparkinson.org/

THIS RESOURCE IS NO LONGER IN SERVICE, documented on March 28, 2017. Foundation that helps junior physicians and neuroscientists continue their research on Parkinson's Disease and related disorders, with financial support for professional and intellectual development. It promotes an international community of researchers, focusing on the young enthusiastic investigators and clinicians who might otherwise be forced to abandon their ideas and efforts.

Proper citation: Melvin Yahr International Parkinson's Disease Foundation (RRID:SCR_001652) Copy   

•   Source: SciCrunch Registry

http://www.parkinson.ca

A not-for-profit, volunteer based charity whose purpose is to find a cure for Parkinson's disease through research, advocacy, education and support services. Parkinson Society Canadas leads initiatives that include: raising funds for research through national events; funding research, movement disorder clinics, and outreach programs across Canada; staffing a national Information and Referral Centre; developing educational and information materials; providing up to date detailed information about Parkinson's disease; and providing support for regional partners to better meet the needs of people living with Parkinson's services. Researchers can apply for various funding awards and fellowships by following the funding process outlined by Parkinson Society Canada.

Proper citation: Parkinson Society Canada (RRID:SCR_002014) Copy   

•   Source: SciCrunch Registry

https://www.wtccc.org.uk/

Consortium of 50 research groups across the UK to harness the power of newly-available genotyping technologies to improve our understanding of the aetiological basis of several major causes of global disease. The consortium has gathered genotype data for up to 500,000 sites of genome sequence variation (single nucleotide polymorphisms or SNPs) in samples ascertained for the disease phenotypes. Analysis of the genome-wide association data generated has lead to the identification of many SNPs and genes showing evidence of association with disease susceptibility, some of which will be followed up in future studies. In addition, the Consortium has gained important insights into the technical, analytical, methodological and biological aspects of genome-wide association analysis. The core of the study comprised an analysis of 2,000 samples from each of seven diseases (type 1 diabetes, type 2 diabetes, coronary heart disease, hypertension, bipolar disorder, rheumatoid arthritis and Crohn's disease). For each disease, the case samples have been ascertained from sites widely distributed across Great Britain, allowing us to obtain considerable efficiencies by comparing each of these case populations to a common set of 3,000 nationally-ascertained controls also from England, Scotland and Wales. These controls come from two sources: 1,500 are representative samples from the 1958 British Birth Cohort and 1,500 are blood donors recruited by the three national UK Blood Services. One of the questions that the WTCCC study has addressed relates to the relative merits of these alternative strategies for the generation of representative population cohorts. Genotyping for this main Case Control study was conducted by Affymetrix using the (commercial) Affymetrix 500K chip. As part of this study a total of 17,000 samples were typed for 500,000 SNPs. There are two additional components to the study. First, the WTCCC award is part-funding a study of host resistance to infectious diseases in African populations. The same approach has been used to type 2,000 cases of tuberculosis (TB) and 2,000 cases of malaria, as well as 2,000 shared controls. As well as addressing diseases of major global significance, and extending WTCCC coverage into the area of infectious disease, the inclusion of samples of African origin has obvious benefits with respect to methodological aspects of genome-wide association analysis. Second, the WTCCC has, for four additional diseases (autoimmune thyroid disease, breast cancer, ankylosing spondylitis, multiple sclerosis), completed an analysis of 15,000 SNPs designed to represent a large proportion of the known non-synonymous coding SNPs across the genome. This analysis has been performed at the WTSI using a custom Infinium chip (Illumina). Data release The genotypic data of the control samples (1958 British Birth Cohort and UK Blood Service) and from seven diseases analyzed in the main study are now available to qualified researchers. Summary genotype statistics for these collections are available directly from the website. Access to the individual-level genotype data and summary genotype statistics is by application to the Consortium Data Access Committee (CDAC) and approval subject to a Data Access Agreement. WTCCC2: A further round of GWA studies were funded in April 2008. These include 15 WTCCC-collaborative studies and 12 independent studies be supported totaling approximately 120,000 samples. Many of the studies represent major international collaborative networks that have together assembled large sample collections. WTCCC2 will perform genome-wide association studies in 13 disease conditions: Ankylosing spondylitis, Barrett's oesophagus and oesophageal adenocarcinoma, glaucoma, ischaemic stroke, multiple sclerosis, pre-eclampsia, Parkinson's disease, psychosis endophenotypes, psoriasis, schizophrenia, ulcerative colitis and visceral leishmaniasis. WTCCC2 will also investigate the genetics of reading and mathematics abilities in children and the pharmacogenomics of statin response. Over 60,000 samples will be analyzed using either the Affymetrix v6.0 chip or the Illumina 660K chip. The WTCCC2 will also genotype 3,000 controls each from the 1958 British Birth cohort and the UK Blood Service control group, and the 6,000 controls will be genotyped on both the Affymetrix v6.0 and Illumina 1.2M chips. WTCCC3: The Wellcome Trust has provided support for a further round of GWA studies in January 2009. These include 5 WTCCC-collaborative studies to be carried out in WTCCC3 and 5 independent studies, across a range of diseases. Many of the studies represent major international collaborative networks that have together assembled large sample collections. WTCCC3 will perform genome-wide association studies in the following 4 disease conditions: primary biliary cirrhosis, anorexia nervosa, pre-eclampsia in UK subjects, and the interactions between donor and recipient DNA related to early and late renal transplant dysfunction. The WTCCC3 will also carry out a pilot in a study of the genetics of host control of HIV-1 infection. Over 40,000 samples will be analyzed using the Illumina 660K chip. The WTCCC3 will utilize the 6,000 control genotypes generated by the WTCCC2.

Proper citation: Wellcome Trust Case Control Consortium (RRID:SCR_001973) Copy   

•   Source: SciCrunch Registry

http://cerad.mc.duke.edu/

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 4, 2023.Consortium that developed brief, standardized and reliable procedures for the evaluation and diagnosis of patients with Alzheimer's disease (AD) and other dementias of the elderly. These procedures included data forms, flipbooks, guidebooks, brochures, instruction manuals and demonstration tapes, which are now available for purchase. The CERAD assessment material can be used for research purposes as well as for patient care. CERAD has developed several basic standardized instruments, each consisting of brief forms designed to gather data on normal persons as well as on cognitively impaired or behaviorally disturbed individuals. Such data permit the identification of dementia based on clinical, neuropsychological, behavioral or neuropathological criteria. Staff at participating CERAD sites were trained and certified to administer the assessment instruments and to evaluate the subjects enrolled in the study. Cases and controls were evaluated at entry and annually thereafter including (when possible) autopsy examination of the brain to track the natural progression of AD and to obtain neuropathological confirmation of the clinical diagnosis. The CERAD database has become a major resource for research in Alzheimer's disease. It contains longitudinal data for periods as long as seven years on the natural progression of the disorder as well as information on clinical and neuropsychological changes and neuropathological manifestations., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Proper citation: CERAD - Consortium to Establish a Registry for Alzheimer's Disease (RRID:SCR_003016) Copy   

•   Source: SciCrunch Registry

http://www.brainbank.mclean.org/

Biomaterial supply resource that acquires, processes, stores, and distributes postmortem brain specimens for brain research. Various types of brain tissue are collected, including those with neurological and psychiatric disorders, along with their parents, siblings and offspring. The HBTRC maintains an extensive collection of postmortem human brains from individuals with Huntington's chorea, Alzheimer's disease, Parkinson's disease, and other neurological disorders. In addition, the HBTRC also has a collection of normal-control specimens.

Proper citation: Harvard Brain Tissue Resource Center (RRID:SCR_003316) Copy   

•   Source: SciCrunch Registry

http://www.neurosci.ucsd.edu/

THIS RESOURCE IS NO LONGER IN SERVICE, documented August 31, 2016. The Laboratory of Experimental Neuropathology is engaged in the study of neurodegenerative disease, including Alzheimer's, Parkinson's, and the dementia of HIV encephalitis. It contains a large bank of materials available to fellow investigators including images, publications, and lab safety. Fellow Investigators and Collaborators may request materials from the brain bank. Technologies employed by the laboratory include immunocytochemistry, neurochemistry, molecular genetics, transgenic models of disease, and imaging by scanning laser confocal microscopy.

Proper citation: UCSD Experimental Neuropath Laboratory (RRID:SCR_004906) Copy   

•   Source: SciCrunch Registry

https://www.bannerhealth.com/research/locations/sun-health-institute/programs/body-donation

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 11, 2023. An autopsy-based, research-devoted brain bank, biobank and biospecimen bank that derives its human donors from the Arizona Study of Aging and Neurodegenerative Disease (AZSAND), a longitudinal clinicopathological study of the health and diseases of elderly volunteers living in Maricopa county and metropolitan Phoenix, Arizona. Their function is studied during life and their organs and tissue after death. To date, they have concentrated their studies on Alzheimer's disease, Parkinson's disease, heart disease and cancer. They share the banked tissue, biomaterials and biospecimens with qualified researchers worldwide. Registrants with suitable scientific credentials will be allowed access to a database of available tissue linked to relevant clinical information, and will allow tissue requests to be initiated., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Proper citation: Brain and Body Donation Program (RRID:SCR_004822) Copy   

•   Source: SciCrunch Registry

http://www.cumc.columbia.edu/dept/taub/index.html

An institute which conducts research of Alzheimer's, Parkinson's and other age-related brain diseases. This organization also provides clinical evaluations to patients with memory problems, Alzheimer's disease or other types of dementia. Furthermore, the institute leads multi-center clinical trials for the treatment and prevention of Alzheimer's, Parkinson's and other age-related brain diseases. There is a brain donation program for enrolled/examined patients. The Education Core of the Taub Institute sponsors community events and Continuing Medical Education programs, as well as the distribution of periodic newsletters and brochures highlighting research developments and other Alzheimer's topics.

Proper citation: Taub Institute for Research on Alzheimers Disease and the Aging Brain (RRID:SCR_008802) Copy   

•   Source: SciCrunch Registry

http://madrc.mgh.harvard.edu/

An Alzheimer's disease research center which supports new research and enhances ongoing research by providing core support to bringing together behavioral, biomedical, and clinical scientists. The Center conducts multidisciplinary research, trains scientists, and spreads information about Alzheimer's disease and related disorders to the general public. The principal goal of the Massachusetts ADRC is to support research in aging, Alzheimer's Disease and other related disorders. Researchers work with national and international multi-disciplinary teams to understand: normal aging, the transition from normal aging to mild forms of memory problems, and the later stages of dementia. The Massachusetts ADRC has an active brain donation program at the Massachusetts General Hospital (MGH) for patients as well as subjects enrolled in research studies.

Proper citation: Massachusetts Alzheimer's Disease Research Center (RRID:SCR_008764) Copy   

•   Source: SciCrunch Registry

http://www.ttuhsc.edu/centers/aging/giabrainbank.aspx

The Brain Bank was developed with two service-minded objectives: provide a free brain autopsy to confirm clinical diagnosis of dementia, and collect, bank and provide brain tissue to qualified scientific researchers studying diseases related to dementia. By working together, patients and researchers can help us understand the origins of neurodegenerative disease and eventually improve the treatment and care of dementia. The clinical diagnosis of Alzheimer's disease can only be confirmed by brain autopsy, or the examination of brain tissue after death. This examination will determine a patients's precise type of dementia. To confirm the diagnosis of Alzheimer's, for example, the brain tissue is examined for amyloid plaques and neurofibrillary tangles by a neuropathologist. The presence of these plaques and tangles will verify the clinical diagnosis of Alzheimer's disease. While it is important to us to enroll patients with dementia, it is equally important to enroll people with no dementia. These subjects are termed as controls and the brain tissue from controls will enable researchers to make comparisons to brain tissue from dementia patients. We are seeking donations from individuals who have had an age-related neurodegenerative disease like Alzheimer's, Parkinson's, Lewy Body or other related dementia.

Proper citation: GIA Brain Bank Program (RRID:SCR_008877) Copy   

•   Source: SciCrunch Registry

http://www.med.upenn.edu/cndr/biosamples-brainbank.html

A brain and tissue bank that contains human brain samples from patients with Alzheimer's disease (AD), Parkinson's disease (PD) and other related neurodegenerative dementias and movement disorders. This brain bank serves as a resource for scientists and researchers, providing access to tissue samples for further research. While priority is given to University of Pennsylvania researchers, this bank will provide requests to researchers not associated with the University of Pennsylvania. This tissue bank accepts donations from those seeing a University of Pennsylvania physician or collaborator.

Proper citation: University of Pennslyvania Brain Bank (RRID:SCR_008820) Copy   

•   Source: SciCrunch Registry

http://brainhealthregistry.org/

A website aimed at recruiting and assessing subjects for all types of neuroscience studies with the internet. The hope is to accelerate various types of observational studies and clinical trials, and also reduce costs. They are interested in having people, including healthy subjects of all ages, join the registry. Joining only takes a few minutes. The web-based project is designed to speed up cures for Alzheimer's, Parkinson's and other brain disorders. It uses online questionnaires and online neuropsychological tests (which are very much like online brain games).

Proper citation: Brain Health Registry (RRID:SCR_010230) Copy   

•   Source: SciCrunch Registry

https://scicrunch.org/kravitz2

Dataset of the spike and laser timestamps from Kravitz, Owen and Kretizer's 2012 paper "Optogenetic identification of striatal projection neuron subtypes during in vivo recordings." The code will analyze spike trains around laser pulses to determine if a cell is significantly activated by the laser, and therefore expresses an excitatory opsin, such as channelrhodopsin-2. It returns an excel sheet that simply identifies the activated cells.

Proper citation: Kravitz Dataset 2 (RRID:SCR_000296) Copy   

•   Source: SciCrunch Registry

http://med.emory.edu/ADRC/research/core_neurology_database.html

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on June 9, 2025. A database which retains extensive clinical information about study subjects recruited by the Alzheimer's Disease Research Center Clinical Core, as well as other individuals with neurological diseases. In addition to clinical information, the database has basic demographics, medical history (including risk factors such as smoking), and a detailed family history from all subjects. Some entries have neuropsychological measures. Users can access a Summary Database which contains the most commonly requested variables. A data dictionary describing the variables in the Summary Database is available.

Proper citation: Emory Neurology Database (RRID:SCR_005277) Copy   

•   Source: SciCrunch Registry

http://www.physionet.org/physiobank/database/gaitndd/

Database of records from patients with Parkinson's disease (n = 15), Huntington's disease (n = 20), or amyotrophic lateral sclerosis (n = 13). Records from 16 healthy control subjects are also included here. The raw data were obtained using force-sensitive resistors, with the output roughly proportional to the force under the foot. Stride-to-stride measures of footfall contact times were derived from these signals.

Proper citation: Gait Dynamics in Neuro-Degenerative Disease Data Base (RRID:SCR_006979) Copy   

•   Source: SciCrunch Registry

http://www.physionet.org/physiobank/database/gaitpdb/

Database that contains measures of gait from 93 patients with idiopathic PD (mean age: 66.3 years; 63% men), and 73 healthy controls (mean age: 66.3 years; 55% men). The database includes the vertical ground reaction force records of subjects as they walked at their usual, self-selected pace for approximately 2 minutes on level ground. Underneath each foot were 8 sensors (Ultraflex Computer Dyno Graphy, Infotronic Inc.) that measure force (in Newtons) as a function of time. The output of each of these 16 sensors has been digitized and recorded at 100 samples per second, and the records also include two signals that reflect the sum of the 8 sensor outputs for each foot. This database also includes demographic information, measures of disease severity (i.e., using the Hoehn & Yahr staging and/or the Unified Parkinson's Disease Rating Scale) and other related measures (available in HTML or xls spreadsheet format). A subset of the database includes measures recorded as subjects performed a second task (serial 7 subtractions) while walking, which shows excerpts of swing time series from a patient with PD and a control subject, under usual walking conditions and when performing serial 7 subtractions. Under usual walking conditions, variability is larger in the patient with PD (Coefficient of Variation = 2.7%), compared to the control subject (CV = 1.3%). Variability increases during dual tasking in the subject with PD (CV = 6.5%), but not in the control subject (CV = 1.2%).

Proper citation: Gait in Parkinson's Disease (RRID:SCR_006891) Copy   

•   Source: SciCrunch Registry

http://www.pd-doc.org/Databases/LinkedDatabases/PSGDatabases/ELLDOPAStudy/tabid/161/Default.aspx

THIS RESOURCE IS NO LONGER IN SERVICE, documented August 23, 2016. This site has a dataset from the ELLDOPA study: a multicenter, placebo-controlled, randomized, dose-ranging, double-blind clinical trial of 361 early, mild Parkinson's disease (PD) subjects, not requiring symptomatic medications with a duration from time of diagnosis less than 2 years. A NINDS funded study. The multicenter, placebo-controlled, randomized, dose-ranging, double-blind clinical trial, called the Earlier versus Later Levodopa Therapy in Parkinson Disease (ELLDOPA) study was run by the Parkinson Study Group and sponsored by the National Institute of Neurological Disorders and Stroke (NINDS). The subjects (n=361) were enrolled between September 1998 and August 2001 at 33 sites in the United States and 5 sites in Canada. Despite the known benefit of levodopa in reducing the symptoms of Parkinsons disease, concern has been expressed that its use might hasten neurodegeneration. This study assessed the effect of levodopa on the rate of progression of Parkinsons disease.The primary analysis assessed the doseresponse relationship between the assigned doses and the worsening of parkinsonism, as indicated by the changes in the total score on the UPDRS between the baseline visit and week 42. Washout of study drug occurred during weeks 40-42.

Proper citation: Earlier versus Later Levodopa Therapy in Parkinson Disease (RRID:SCR_001150) Copy   

•   Source: SciCrunch Registry

http://www.PDtrials.org

THIS RESOURCE IS NO LONGER IN SERVICE, documented August 23, 2016. A collaborative initiative of Parkinson's organizations dedicated to increasing education and awareness about clinical research. PDtrials provides up-to-date information on Parkinson's disease trials currently enrolling participants in the U.S. and Canada, as well as information about Parkinson's studies for people living with PD, their families and caregivers. Researchers can list their own trials on the PDtrials website. Patients can browse trial listings by type, location, symptom, or keyword.

Proper citation: PDtrials- Parkinsons Disease Clinical Trials (RRID:SCR_002027) Copy   

•   Source: SciCrunch Registry

http://www.worldpdcongress.org

A nonprofit organization dedicated to providing an international forum for the latest scientific discoveries, medical practices and caregiver initiatives related to Parkinson's disease. It hosts the annual World Parkinson Congress, an event which focuses on bringing physicians, scientists, allied health professionals, caregivers and people diagnosed with Parkinson's disease together, in order to create a global dialogue that will help expedite treatment practices and the discovery of a cure .

Proper citation: World Parkinson Congress (RRID:SCR_002034) Copy   

•   Source: SciCrunch Registry

http://www.wpda.org

THIS RESOURCE IS NO LONGER IN SERVICE, documented August 23, 2016. The World Parkinson's Disease Association is an alliance of members from all over the world who have come together to share information about Parkinson's disease. In order to further Parkinson's research and better the condition of those diagnosed with the disease, the Association: establishes computerized connections; takes part in and/or finances research activities; urges pharmaceutical companies and government institutions of the various countries to support the guidelines recommended by the associations of Parkinson's patients; and coordinates and promotes interchange of information among its members with the aim of solving problems of mutual interest.

Proper citation: World Parkinson Disease Association (RRID:SCR_002035) Copy   

•   Source: SciCrunch Registry